Tested and Proven COVID-19 Testing Solutions
MiRXES offers complete COVID-19 testing solutions, starting from sample collection and preservation, through easy and reliable RNA extraction, to tested and proven SARS-CoV-2 RT-PCR diagnostic tests and mutation panels for quick identification of key variants.
Sample Collection & Processing Solutions
May 2021 Update: SARS-CoV-2 Variants
The World Health Organization (WHO) has defined a SARS-CoV-2 isolate as a variant of interest (VOI) if it is phenotypically changed compared to a reference isolate of has a genome with mutations that lead to amino acid changes associated with established or suspected phenotypic implications; AND has been identified to cause community transmission/multiple COVID-19 cases/clusters, or has been detected in multiple countries.
A VOI is further classified as a variant of concern (VOC) if, through a comparative assessment, it has been demonstrated to be associated with:
- Increase in transmissibility of detrimental change in COVID-19 epidemiology;
- Increase in virulence or change in clinical disease presentation; or
- Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics.
Selected WHO-designated SARS-CoV-2 VOCs and selected VOIs, as of 1 June 2021.
First detected in
Characteristic spike mutations
N501Y, 69/70del, 144del, A570D, D614G, P681H, T716I, S982A, D1118H
E484K, N501Y, D80A, D215G, 241/243del, K417N, D614G, A701V
E484K, N501Y, L18F, T20N, P26S, D138Y, R190S, K417T, D614G, H655Y, T1027I, V1176F
L452R, D614G, P681R
E484K, Q52R, A67V, 69/70del, 144del, D614G, Q677H, F888L
L452R, S13I, W152C, D614G
Detection of key SARS-CoV-2 variants by Fortitude RT-PCR test kits
The MiRXES R&D team is constantly tracking the World Health Organization’s designation of new VOCs and VOIs and has performed in silico analyses to determine the sequence homology between the MiRXES Fortitude SARS-CoV2 RT-PCR primers and all SARS-CoV-2 sequences, including those of specific variants.
This table shows the percentage of aligned sequences in the GISAID database that have 100% homology to the primer (probe) sequence of the MiRXES Fortitude series RT-PCR test kits, as of 10 May 2021:
Overall, >99% of aligned sequences have 100% homology to either the ORF or N gene target sequence of MiRXES Fortitude RT-PCR test kits.
Sequence homology with
Fortitude Syndromic Panel
All SARS-CoV-2 ORF target sequences
All SARS-CoV-2 N gene target sequences
B.1.1.7 lineage (UK)
B.1.351 lineage (South Africa)
B.18.104.22.168 (P1) lineage (Brazil)
B.1.617 lineage (India)
B.1.617.2 sub-lineage (India)
B.1.525 lineage (Multiple countries)